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Background:Removal of C-terminal lysine residues that are continuously exposed in lysing ﬁbrin is an established
anti-ﬁbrinolytic mechanism dependent on the plasma carboxypeptidase TAFIa, which also removes arginines
that are exposed at the time of ﬁbrinogen clotting by thrombin.
Objective: To evaluate the impact of alterations in ﬁbrin structure mediated by constitutive carboxypeptidase
activity on the function of ﬁbrin as a template for tissue plasminogen activator-(tPA) induced plasminogen acti-
vation and its susceptibility to digestion by plasmin.
Methods and results:Weused the stable carboxypeptidase B (CPB), which shows the same substrate speciﬁcity as
TAFIa. If 1.5 – 6 μM ﬁbrinogen was clotted in the presence of 8 U/mL CPB, a denser ﬁbrin network was formed
with thinner ﬁbers (the median ﬁber diameter decreased from 138 – 144 nm to 89 – 109 nm as established
with scanning electron microscopy). If clotting was initiated in the presence of 5 – 10 μM arginine, a similar
decrease in ﬁber diameter (82 -95 nm)wasmeasured. The ﬁne structure of arginine-treated ﬁbrin enhanced plas-
minogen activation by tPA, but slowed down lysis monitored using ﬂuorescent tPA and confocal lasermicroscopy.
However, if lysis was initiatedwith plasmin in CPB-treated ﬁbrin, the rate of dissolution increased to a degree cor-
responding to doubling of the plasmin concentration.
Conclusion: The present data evidence that CPB activity generatesﬁne-meshﬁbrinwhich ismore difﬁcult to lyse by
tPA, but conversely, CPB and plasmin together can stimulate ﬁbrinolysis, possibly by enhancing plasmin diffusion.© 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY license.Introduction
Binding of tissue-type plasminogen activator (tPA) and plasminogen
to ﬁbrin is a prerequisite for efﬁcient ﬁbrinolysis (reviewed in [1]), in
the course of which the generated plasmin provides a positive feed-
back loop through exposure of new carboxyl terminal lysines that pro-
mote ﬁbrinolysis primarily through plasminogen and plasmin binding
[2]. The amplifying effect of C-terminal lysines on plasminogen activa-
tion and the protection of the bound plasmin against its major plasma
inhibitor α2-plasmin inhibitor is counterbalanced by the action of
thrombin activatable ﬁbrinolysis inhibitor (TAFI, or carboxypeptidase
U), an exopeptidase that removes basic amino acids (arginine andxypeptidase N; TAFI, thrombin
ogen activator.
ity, Department of Medical
. Tel.: +36 1 4591500/60035;
.
. Open access under CC BY license.lysine) from theC-terminal of peptides (reviewed in [3]). TAFI is present
in blood plasma in zymogenic form and it is activated by thrombin-
thrombomodulin complex to TAFIa, but its activity decays with a half-
life of several minutes [4]. A distinct, constitutively active enzyme, car-
boxypeptidase N (CPN) is also present in plasma [5,6]. It binds ﬁbrin
and can be detected in the structure of plasma clots [7,8]. Despite the
identical primary speciﬁcity of TAFIa and CPN the anti-ﬁbrinolytic ac-
tion of CPN is only a fraction of that of TAFIa even after an activating
cleavage by plasmin [9]. The lysis of whole blood clots immersed in
tPA is surprisingly insensitive to the action of CPN; no impairment of
lysis is observed under conditions when CPN removes lysyl residues
from ﬁbrin at a rate corresponding to 50% of that by TAFIa [10]. The
background of the differential anti-ﬁbrinolytic potential of CPN and
TAFI is still not clariﬁed.
Another determinant of ﬁbrinolytic efﬁciency is ﬁbrin structure,
which as a cofactor for tPA, regulates plasminogen activation, and sus-
ceptibility to plasmin digestion (reviewed in [11]). The initial structure
and subsequent rearrangements of ﬁbrin during lysismean that binding
events, plasminogen activation and ﬁbrin digestion can be affected in
complex ways, sometimes in opposite directions [12]. With this in
mind, a question arises, can carboxypeptidase activity expressed during
clot formation and dissolution induce structural changes that modulate
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contradictory data on the association of TAFI and thrombotic events
reported in epidemiological studies. TAFI levels in circulation are regu-
lated by known gene polymorphisms, but the connectionwith coronary
heart disease [13] or stroke [14] is less clear. In the absence of anymech-
anistic evidence for antithrombotic effects of TAFI the controversy that
both high and low thrombotic risk can be accompanied by elevated
TAFI levels in plasma [15–19] is currently explained by the different
methods used for determination of TAFIa activity or TAFI antigen and
the different sensitivity of the detection assays for TAFI isoforms [20].
However, additional levels of complexity may still remain uncovered
as suggested by the fact that some aspects of TAFIa mechanism of
action established in vitro remain a puzzle. For example, if ﬁbrin con-
tainingα2-plasmin inhibitor or plasma clots are supplemented with in-
creasing concentrations of TAFIa, a threshold concentration can be
reached beyond which TAFIa is proﬁbrinolytic [21]. One hypothesis for
this phenomenon is the removal of lysine452 of α2-plasmin inhibitor
by carboxypeptidases [21], but this is difﬁcult to reconcile with the ﬁnd-
ings that the C-terminal lysine in the inhibitor is not essential for its in-
teraction with plasmin [22]. The completely normal phenotype of TAFI
knock-out mice (including hemostasis at basal state or if challenged
by a variety of prothrombotic stimuli) [23] also raises the possibility
for subtle TAFI effects in vivo beyond the known mechanism of action.
Thus, the details of TAFI function still require further elaboration despite
its well-documented anti-ﬁbrinolytic action in vitro. The present study
addresses the modulation of ﬁbrinolysis related to ﬁbrin structure
which is altered as a consequence of basic carboxypeptidase activity.
Materials and methods
Plasminogen-depleted human ﬁbrinogen, streptokinase and porcine
carboxypeptidase B (CPB) were from Calbiochem (La Jolla, CA). The
chromogenic substrate for plasmin, Spectrozyme-PL (H-D-norleucyl-
hexahydrotyrosyl-lysine-p-nitroanilide) was from American Diagnostica
(Pfungstadt, Germany) and tPA was from Boehringer Ingelheim
(Germany). Bovine thrombin was purchased from Serva (Heidelberg,
Germany) and further puriﬁed by ion-exchange chromatography on
sulfopropyl-Sephadex yielding a preparation with speciﬁc activity of
2100 IU/mg [24] and1 IU/mLwas considered equivalent to approximate-
ly 10.7 nM by active site titration [25]. Alexa Fluor® 546-conjugated
ﬁbrinogen was the product of Invitrogen Life Technologies, Budapest,
Hungary. Human plasminogen was puriﬁed by afﬁnity chromatography
on Lysine-Sepharose from citrated human plasma provided by the
Hungarian Blood Supply Service [26]. The generation of plasmin from
the zymogen and determination of its active concentration were
performed as previously described [27]. Bloodwas collected fromhealthy
volunteers with venipuncture in 10 mM trisodium-citrate (ﬁnal concen-
tration) and following 10-min centrifugation at 2,000 g the top ¾ of the
plasma layer was used for the measurements within 4 h.
Turbidimetric ﬁbrinolytic assays
In 96-well microtiter plates, 6 μM ﬁbrinogen in 10 mMHEPES buffer
pH 7.4 containing 150 mMNaCl and arginine or CPB at various concen-
trationsweremixedwith 20 nM thrombin in a total volumeof 100 μl. In
the assays when lysis was initiated by surface tPA, ﬁbrinogen also
contained 1 μM plasminogen and following 30 min clotting, tPA was
applied to the surface of clots at 15 nM. The concentration of CPB that
produced maximum effect in this assay (8 U/mL) was applied in the
rest of the experiments in this study. In the assays when lysis was initi-
ated by tPAdispersed in the clot,ﬁbrinogen contained 0.25 μMplasmin-
ogen and 0.1 nM tPA was added together with thrombin. In the assays
when lysis was initiated by plasmin its concentrations were chosen to
yield complete dissolutionwithin 5 h; in the range 2-10 nM for plasmin
uniformly dispersed in the clot and 0.5 – 2 μMfor plasmin applied to the
clot surface as described previously [28,29]. Clot formation anddissolution was followed by measuring the light absorbance at
340 nm at 37 °C with a Zenyth 200rt microplate spectrophotometer
(Anthos Labtec Instruments GmbH, Salzburg, Austria). For adequate
comparison of lytic rates from measurements, in which different maxi-
mum turbidity values were reached despite the identical quantities of
ﬁbrin, the absorbance values were evaluated in normalized form [30].
The time needed to reduce the turbidity of the clot to a given fraction
of the maximal value (t0.5 to reach 0.5Amax, t0.1 reach 0.1Amax) was
used as a quantitative parameter of ﬁbrinolytic activity. In certain
cases plasma containing various concentrations of added arginine and
CPB was clotted with 15 nM thrombin and 12.5 mM CaCl2. If plasma
clot dissolution was mediated by tPA dispersed in the clot, tPA was
added at 0.8 nM prior clotting, whereas the concentration of tPA ap-
plied to the surface of plasma clots was 30 nM.
Scanning electron microscopic (SEM) studies
Fibrin clots of 50 μl volume were prepared in duplicate: ﬁbrinogen
(at concentration in the range 1.5 – 6 μM) in 10 mM HEPES buffer
pH 7.4 containing 150 mM NaCl and the additives (arginine or CPB)
was clotted with 20 nM thrombin at 37 °C for 30 min. Thereafter clots
were placed into 10 mL 100 mM Na-cacodylate pH 7.2 buffer for 24 h
at 4 °C. Following repeated washes with the same buffer, samples
were ﬁxed in 1%(v/v) glutaraldehyde for 16 h. The ﬁxed samples were
dehydrated in a series of ethanol dilutions (20 – 96%(v/v)), 1:1 mixture
of 96%(v/v) ethanol/acetone and pure acetone followed by critical point
drying with CO2 in E3000 Critical Point Drying Apparatus (Quorum
Technologies, Newhaven, UK). The specimens were mounted on adhe-
sive carbon discs, sputter coated with gold in SC7620 Sputter Coater
(Quorum Technologies, Newhaven, UK) and images were taken with
scanning electron microscope EVO40 (Carl Zeiss GmbH, Oberkochen,
Germany). The SEM images were analyzed to determine the diameter
of the ﬁbrin ﬁbers using self-designed program functions running
under the Image Processing Toolbox v. 8.2 of Matlab 8.1.0.604
(R2013a) (TheMathworks, Natick, MA) as previously described [12,31].
Plasminogen activation assay
In 96-well microtiter plates, 6 μM ﬁbrinogen in 10 mMHEPES buffer
pH 7.4 containing 150 mMNaCl, 0.5 μMplasminogen and additives (ar-
ginine or CPB) was clotted with 25 nM thrombin in a volume of 80 μl.
After 30 min at 37 °C 60 μl of 15 nM tPA and 0.6 mM Spectrozyme-PL
in 10 mM HEPES, 150 mM NaCl pH 7.4 were placed on the surface of
the clot. The forming plasmin generated p-nitroaniline, the absorbance
ofwhichwas continuously recorded at 405 nm(A405)with Zenith 200rt
spectrophotometer. The measured values were plotted versus time
squared (t2) yielding a linear relationship according to the equation
ΔA405 = 0.5εk1kcat[tPA] t2 [32], where ε = 12.6 mM-1 cm-1 is the ex-
tinction coefﬁcient of p-nitroaniline [33], k1 = 350 min-1 is the turn-
over number of plasmin on Spectrozyme-PL [33], kcat and [tPA] are the
catalytic constant for plasminogen activation and the concentration of
tPA in the reactive layer on the surface of ﬁbrin, respectively [34]. The
termVapp = kcat[tPA] is equivalent to the apparentmaximal rate of plas-
minogen activation in the reactive layer of ﬁbrin and was determined
from linear regression according to the abovementioned equation
(Curve ﬁtting toolbox v. 3.3.1 of Matlab 2013a).
Confocal microscopic imaging
Fibrin clots were prepared from 6 μM ﬁbrinogen, 2% of which was
Alexa Fluor® 546-labelled in 10 mM HEPES buffer pH 7.4 containing
150 mM NaCl, 1.5 μM plasminogen and the tested additives with
15 nM thrombin for 30 min at room temperature in sterile, uncoated
IBIDI VI 0.4 μ-slides (Ibidi GmbH, Martinsried, Germany). Thereafter
50 nM tPA-YFP (tPA with Yellow Fluorescent Protein fused to its C-
terminal expressed using pFastBac-tPA as previously described) [12]
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length 488 nm, emissionwavelength 525 nm for tPA-YFP detection and
excitation wavelength 543 nm, emission wavelength 575 nm for
Alexa546-ﬁbrinogen detection) was monitored with Confocal Laser
Scanning System LSM710 (Carl Zeiss GmbH, Jena, Germany) taking se-
quential images of the ﬂuid-ﬁbrin interface at a distance of approxi-
mately 50 μm from the chamber surface with identical exposures and
laser intensities using a Plan-Neoﬂuar 20x/0.5 objective. It should be
noted that the 10 – 20 μm ﬂuorescent aggregates present in the com-
mercial Alexa Fluor® 546-labelled ﬁbrinogen were not centrifuged
before clotting as done in our earlier work [35], but these were pre-
served and used as position markers in the ﬁbrin.
Statistical analysis
The distribution of the data on ﬁber diameterwas analyzed according
to an algorithm used previously [12,31]: theoretical distributions were
ﬁtted to the empirical data sets and compared using Kuiper test and
Monte Carlo simulation procedures. The statistical evaluation of other
experimental measurements in this report was performed with
Kolmogorov-Smirnov test (Statistics Toolbox 8.2 of Matlab R2013a).
Results
Structural modiﬁcations of ﬁbrin related to CPB activity or presence of
arginine
We have previously shown [12], when CPB was used as a stable an-
alogue of TAFIa to evaluate the impact of removal of carboxyl terminal
lysines on the kinetics of ﬁbrinolysis, that the presence of CPB during ﬁ-
brinogen clotting modiﬁes the turbidity of the clots before initiation of
lysis, which suggested changes in the structure of ﬁbrin. SEM imaging
provided direct evidence for the alteration of the ﬁbrin structure related
to the action of CPB (Fig. 1A). Morphometric analysis of the SEM images
(Fig. 1B) revealed that the ﬁber diameter decreased by 21 – 25% in CPB-
treated clots prepared from ﬁbrinogen at physiologically relevant con-
centration (1.5 – 6 μM). Because the native ﬁbrinogen molecule does
not contain any substrate (C-terminal lysine or arginine) for CPB, the
single target of CPB action in this puriﬁed system could be the arginine
residues in the ﬁbrinopeptides newly cleaved by thrombin in the pro-
cess of clotting. If all new C-terminal arginines were released from the
4 ﬁbrinopeptides derived from each ﬁbrinogen molecule, an increment
of 25 – 50 μMwould be expected in the local concentration of arginine
in clots prepared from 2 – 4 mg/mL ﬁbrinogen (a prediction supported
by direct measurements of arginine release by TAFIa in ﬁbrin: 10 μM in
5 min after clotting [36]). As evidenced by the morphometric data
(Fig. 1C), addition of arginine at 5 – 20% of this maximal concentration
caused changes in the structure of ﬁbrin comparable to those induced
by the action of CPB (Fig. 1B). Considering the normal plasma level of ar-
ginine of about 100 μM [37] and these subtle structural alterations in ﬁ-
brin, inclusion of micromolar arginine appears to be essential for
appropriate modelling of the physiological conditions when ﬁbrin
structure-dependent processes are evaluated with in vitro assays.
Kinetics of plasminogen activation and ﬁbrin dissolution
On amicroscopic scale (Fig. 2), tPA-induced lysis of ﬁbrinmodiﬁed by
CPB was signiﬁcantly slowed down with a granular pattern of accumula-
tion of tPA on the surface of the clot similar to that of native ﬁbrin. On a
macroscopic scale of lytic kinetics, CPB had a maximal inhibitory effect
at 8 U/mL in the assay when tPA was added to the surface of pre-
formed clots containing plasminogen, as shown in Fig. 3. A similar level
of inhibition of lysis was also seen in clots formed in the presence of argi-
nine at concentration as low as 2 μM. Although with either CPB or argi-
nine the acceleration seen at later stages of lysis in pure ﬁbrin was
missing and despite the identical time to complete dissolution, the lysiskinetics were somewhat different with CPB or arginine, suggesting a dif-
ferent mechanism of action. To address this difference two assays were
used; one that monitored solely the generation of plasmin (Fig. 4) and a
second one that bypassed the stage of plasminogen activation (Fig. 5).
The effects of CPB and arginine on plasminogen activation by tPA on
the surface of ﬁbrin was studied in isolation using the substrate
Spectrozyme-PL to follow plasmin generation. As expected, plasmin
generation was inhibited in the presence of CPB, presumably resulting
from removal of newly exposed C-terminal lysine binding sites in
ﬁbrin (Fig. 4). In contrast however, ﬁbrin formed in the presence of
arginine proved to be a better template for plasminogen activation
than the native ﬁbrin structure (Fig. 4), despite the overall inhibiting
effect of arginine on tPA-induced ﬁbrin degradation seen in Fig. 3. It
is noteworthy that arginine at identical concentrations does not
affect plasminogen activation by tPA in ﬁbrin-free systems (data not
shown).
When plasminwas added to the surface of ﬁbrin, slower lysis was ob-
served similarly to the tPA-induced lysis, if clots were formed in the pres-
ence of arginine (Fig. 5A). Quite unexpectedly, CPB rendered ﬁbrin more
susceptible to lysis by plasmin added to the surface of the clot (Fig. 5B).
The complete lysis of CPB-treated ﬁbrin was faster (Table 1) and non-
treated ﬁbrin was dissolved by 2 μM plasmin at approximately the
same rate as CPB-modiﬁed ﬁbrin by 1 μM plasmin (no signiﬁcant differ-
ence between the values for these two states in the 4th and 5th column
of Table 1). However, if plasmin was homogeneously dispersed within
the clot, neither inhibitory effect of arginine, nor stimulatory effect of
CPB could be observed (data not shown). The discordant effects of the
modulators in the two assay formats indicate that at least in part their ef-
fects arise from the variations in the penetration of plasmin inﬁbrin of dif-
ferent structure.Fibrinolysis in plasma environment
In line with the effects observed with puriﬁed ﬁbrinolytic compo-
nents (Fig. 3), arginine and CPB retarded the dissolution of plasma
clots by tPA (Fig. 6). However, CPB inhibited plasma clot lysis at lower
concentrations than used in the puriﬁed systems above. If tPA was uni-
formly dispersed in the plasma prior clotting, 0.1 U/mL CPB prolonged
the half lysis time more than two-fold, whereas the effect of arginine
at physiologically relevant concentration (100 μM) was minimal
(Fig. 6B). If tPA was applied to the surface of pre-formed clots, the effect
of this arginine was equivalent to 0.4 U/mL CPB (Fig. 6A).Discussion
Since the discovery of TAFI [38] its anti-ﬁbrinolytic action has been
largely attributed to the removal of plasmin-generated C-terminal
lysines in the ﬁbrinmatrix, but it has been difﬁcult to show convincingly
that TAFI levels affect myocardial infarction or stroke outcomes at a
population level or to explain the different anti-ﬁbrinolytic impact of
TAFI and plasma CPN. In the present study we used CPB, a homologous,
but stable carboxypeptidase with speciﬁcity for basic amino acids
and addressed alternative or additional factors that could modulate
its anti-ﬁbrinolytic function. The application of CPB overcomes the
short half-life of TAFIa of approximately 10 min [4], has the technical
advantage that it does not inactivate plasmin in contrast to TAFIa [36]
and models also the constitutive in vivo activity of CPN at the stage of
ﬁbrin clot formation. Our work identiﬁed two consequences of CPB
activity in ﬁbrin that antagonize the CPB-dependent blockade of the
positive feed-back loop in ﬁbrinolysis based on C-terminal lysine
exposure: 1) enhancement of plasmin activity when the ﬂuid-borne
enzyme attacks the surface of pre-formed clots, probably due to
improved diffusion; and 2) ﬁbrin structure-related acceleration of
plasminogen activation.
Fig. 1. Modiﬁcation of ﬁbrin structure by arginine and carboxypeptidase B. Fibrin clots were prepared in duplicate from ﬁbrinogen at various concentrations and following ﬁxation and
drying imageswere takenwith a scanning electronmicroscope (SEM). A: Representative images of nativeﬁbrin at 6 μM(left panel) andﬁbrin at the same concentration treatedwith 8 U/mL
CPB. Scale bar = 1 μm. B: Effect of CPB on the ultrastructure of ﬁbrin. Morphometric analysis of ﬁbrin was performed on SEM images illustrated in panel A. The diameter of 300 ﬁbres was
measured and their empiric (black histograms) as well as best-ﬁtted theoretical (gray curves) probability density function (PDF) was determined. Median values and interquartile range (in
brackets) are shown for the theoretical distributions of the diameter values. The concentrations of ﬁbrinogen (Fg) indicated on the left side refer to both non-treated and CPB-treated ﬁbrin.
C: Effect of arginine on the ﬁbrin structure. The same morphometric analysis was performed on ﬁbrin prepared from 6 μM ﬁbrinogen containing the concentrations of arginine indicated.
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Fig. 2. Effects of arginine and carboxypeptidase B on the penetration of tPA-YFP into ﬁbrin in the course of lysis. Clots were prepared from ﬁbrinogen containing Alexa546-label,
plasminogen and the indicated additives. tPA-YFP was added to the surface of ﬁbrin (at the top of the images) and the ﬂuid/ﬁbrin interface was monitored by confocal laser scanning
microscopy using double ﬂuorescent tracing (tPA-related ﬂuorescence stains in green, whereas the ﬁbrin is shown in red in these images). The time after the application of tPA-YFP is
indicated, and the scale bar = 50 μm. The numbers in the bottom panels indicate the distance for penetration of tPA-YFP in the clot at 25 min (mean and standard deviation from 3 sam-
ples, the values for arginine and CPB differ from pure ﬁbrin at p b 0.05 level according to Kolmogorov-Smirnov test).
84 A. Kovács et al. / Thrombosis Research 133 (2014) 80–87Degradation of ﬁbrin by plasmin at the surface of the clot
A rather unexpected observation arose from the study of surface ap-
plication of plasmin to ﬁbrin containing CPB (Fig. 5B, Table 1), where in-
creased potency of plasmin was noted. Under the conditions shown,
CPB treatmentwas equivalent to doubling the concentration of plasmin.
This was in contrast to the lack of CPB effect on ﬁbrin digestion when
plasminwas dispersed in the clot (data not shown). Enhanced suscepti-
bility to plasmin could be explained by removal of newly exposed C-
terminal lysines that serve as binding sites for plasmin and retard its
penetration into the lysing clot. The elimination of these retarding inter-
actions shifts the dynamic equilibrium of free and bound plasmin in
favour of the former which is actually engaged in the degradation of
the ﬁbrin matrix. This interpretation of the CPB effect on plasmin-
mediated ﬁbrinolysis is in agreement with earlier ﬁndings that TAFIa
increases the susceptibility of ﬁbrin-bound plasmin to inactivation by
α2-plasmin inhibitor [39] due to elimination of binding sites essential
for the reduction of the inhibition rate constant by orders of magnitude
compared to ﬁbrin-free solution [27]. This enhancement of plasminFig. 3. Arginine and carboxypeptidase B in ﬁbrin clot lysis assay. Fibrin clots containing
plasminogen and the indicated additiveswere prepared, tPAwas added to the surface and
the absorbancewas continuouslymeasured at 340 nm (turbidity, A340 is presented in rel-
ative units, normalized for maximal value of absorbance of each individual curve). Mean
values of 8 measurements from 3 independent experiments (continuous lines with sym-
bols at every 10th measured point for identiﬁcation of the curves) and SEM values above
and below mean (gray lines) are shown.action provides an explanation for the observed reversal of the anti-
ﬁbrinolytic effect of TAFI in situationswhen abundant plasmin is formed
at the surface of the clot and thus the major control point of the overall
ﬁbrinolysis is shifted from the stage of plasminogen activation to the ac-
tion of plasmin. Such a loss of TAFI-dependent inhibition of ﬁbrinolysis
has been reported for high concentrations of tPA [40] and other activa-
tors [41], as well as when plasma is supplemented with plasminogen
[42]. The key ﬁnding from the present study that CPB activity favours
the action of plasmin is in line with the predictions of recent theoretical
models ofﬁbrinolysis [43] and provides a clue for understanding the dif-
ference in the anti-ﬁbrinolytic potential of a transiently active (TAFIa)
and constitutive (CPN) carboxypeptidase [9,10].
tPA-mediated ﬁbrinolysis
Although as expected, CPB slows down the tPA-dependent lysis of
both pure ﬁbrin (Figs. 2 & 3) and plasma clots (Fig. 6), the route of actionFig. 4. Plasminogen activation on the surface of ﬁbrin. Fibrin clots containing plasmin-
ogen and the indicated additives were prepared and following addition of tPA and the
plasmin substrate Spectrozyme-PL the absorbance was continuously measured at
405 nm(A405).Meanvaluesof 8measurements from3 independent experiments (contin-
uous lines with symbols at every 5th measured point for identiﬁcation of the curves) and
SEM values above and below mean (gray lines) are shown. Inset: Secondary plots of the
raw data the slopes of which represent the apparentmaximal activation rates of plasmin-
ogen as deﬁned in Materials and methods (1.1 nM/min in the absence of additives,
0.8 nM/min in CPB-treated ﬁbrin, 1.8 nM/min in arginine-modiﬁed ﬁbrin).
Fig. 5. Dissolution of ﬁbrin by plasmin applied to the surface of the clots. Fibrinogen
containing the indicated additives was clotted with thrombin and thereafter plasmin
was applied to its surface and the absorbancewas continuouslymeasured at 340 nm(tur-
bidity, A340 is presented in relative units, normalized for maximal value of absorbance of
each individual curve). Mean values of 8 measurements from 3 independent experiments
(continuous lines with symbols at every 10th measured point for identiﬁcation of the
curves) and SEM values above and below mean (gray lines) are shown. A: Effects of argi-
nine on lysis by 0.5 μM plasmin. B: Effect of 8 U/mL CPB on the lysis of ﬁbrin by plasmin.
Fig. 6. Effects of arginine and carboxypeptidase B on ﬁbrinolysis in plasma environ-
ment. Citrated plasma containing the indicated additives was clotted with thrombin and
recalciﬁcation and ﬁbrinolysis was initiated either by 30 nM tPA added to the surface of
pre-formed clots (A) or by 0.8 nM tPA mixed with thrombin prior clotting (B). Thereafter
the absorbancewas continuously measured at 340 nm (A340). Mean values of 4 measure-
ments from 3 independent experiments (continuous lines with symbols at every 10th
measured point for identiﬁcation of the curves) and SEM values above and below mean
(gray lines) are shown.
85A. Kovács et al. / Thrombosis Research 133 (2014) 80–87of the activator (at the surface or within the clot) profoundly affects its
sensitivity to the action of CPB. The difference in the ﬁbrinolytic out-
come for the two accession routes could be explained by the diffusion-
dependent effects of CPB on plasmin as discussed above (the favorable
CPB effects on plasmin at the clot surface counteract the inhibition of
plasminogen activation, whereas in the absence of such a counter-
balancing factor lower CPB activity is sufﬁcient to inhibit the tPA-
mediated lysis in a homogenous assay format). In addition,we observed
that plasminogen activation on ﬁbrin by ﬂuid-borne tPA is less affected
than expected from earlier studies [36]. In different experimental
setups, where unidirectional diffusion or matrix penetration is not at
issue (e.g. with enzymes uniformly dispersed within ﬁbrin clots), the
cleavage of C-terminal lysines reduces the rate constant of plasminogenTable 1
Impact of carboxypeptidase B on the kinetics of ﬁbrinolysis by plasmin. Fibrin clots were prepa
time needed for a decrease in themaximal absorbance to the fraction values shown in the indic
iments (asterisk indicates differences between values for CPB-treated and non-treated sample
0.5 μM plasmin 1.0 μM plasm
CPB 0 8 U/mL 0
t0.9 7.9 ± 0.7 10.4 ± 0.6* 5.8 ± 0.7
t0.5 75.4 ± 6.7 81.8 ± 2.3 46.5 ± 0.8
t0.3 126.0 ± 9.3 126.3 ± 1.2 77.6 ± 0.9
t0.1 187.0 ± 9.0 165.0 ± 2.6* 126.5 ± 4.1activation by a factor of 2.5 [36]. In contrast, only a 27% decrease in the
plasminogen activation rate on the surface of ﬁbrin can be achieved by
CPB treatment (Fig. 4). This discrepancymaybe explained by a compen-
satory increase in plasminogen activation rate due to the formation of
ﬁne mesh ﬁbrin related to CPB activity.
Interestingly, the same structural alterations were observed in the
presence of arginine at micromolar concentrations (Fig. 1C). Because
in the concentration range up to 250 μM, arginine does not affect plas-
min activity on a small peptide substrate (Spectrozyme PL) and plas-
minogen activation by tPA in ﬁbrin-free systems (data not shown),
measurements with arginine-modiﬁed ﬁbrin proved to be a helpful
tool to discriminate between cleavage of C-terminal lysines andmodiﬁ-
cation of ﬁbrin structure as a background of the CPB effects discussedred and lysis initiated with plasmin at various concentrations as illustrated in Fig. 5B. The
es of t is presented inmin asmean and SD of 8 measurements from 3 independent exper-
s at p b 0.05 level according to Kolmogorov-Smirnov test).
in 2.0 μM plasmin
8 U/mL 0 8 U/mL
3.8 ± 0.3* 5.4 ± 1.4 3.9 ± 0.2
37.0 ± 3.5* 33.1 ± 5.6 23.0 ± 2.6*
68.8 ± 4.0* 54.4 ± 11.1 35.6 ± 6.4*
110.5 ± 3.4* 90.6 ± 19.2 54.5 ± 8.8*
86 A. Kovács et al. / Thrombosis Research 133 (2014) 80–87above. Theminimal inhibitory effect of arginine-modiﬁed ﬁbrin on plas-
min action at the surface (Fig. 5A) precludes a role for ﬁne-mesh struc-
ture in the pro-ﬁbrinolytic effect of CPB (Fig. 5B) and thus supports the
interpretation of the results based on changes in the penetration pattern
of plasmin in ﬁbrin devoid of C-terminal lysines. The deﬁnite accelera-
tion of plasminogen activation on arginine-modiﬁed ﬁbrin (Fig. 4) sup-
ports the conclusion given above that the observed rate of plasmin
generation on CPB-modiﬁed ﬁbrin is the outcome of two opposing ef-
fects; a positive one based on ﬁne-mesh structure and a negative one
based on elimination of C-terminal lysine binding sites that would oth-
erwise promote plasminogen activation.
Out of these ﬁndings a hypothesis is emerging for a causative
relationship between carboxypeptidase activity, arginine release and
structure/function alterations ofﬁbrin. Variations of arginine concentra-
tion within the range used in the present study could arise in vivo from
TAFIa action on ﬁbrinopeptides A and B released by thrombin as report-
ed earlier by direct argininemeasurements in ﬁbrin clots prepared from
physiologically relevant ﬁbrinogen concentrations [36]. Alternative
sources of carboxypeptidase activity at the stage of ﬁbrin formation
(before TAFIa peaks) could be the constitutive plasma CPN and under
pathological conditions even pancreatic CPB [44]. A fraction of the argi-
nine concentration that can bemaximally released from this sourcewas
sufﬁcient to modify the structure of ﬁbrin in a similar way to CPB
(Fig. 1). It is noteworthy that in the course of tPA-mediated lysis of
pureﬁbrin, TAFIa releases both arginine and lysine at increasing concen-
trations in the micromolar range and a ratio that is consistently about
ﬁve-fold in favor of arginine over a period of several hours [36]. This
fact has been largely ignored in the in vitro ﬁbrinolytic studies using
clots prepared from puriﬁed ﬁbrinogen or diluted plasma. Because the
results of the present study indicate that the effects of arginine on ﬁbrin
structure and ﬁbrinolysis are saturable at concentrations approaching
the physiological plasma level of 100 μM [37], and in vitro the genera-
tion of arginine up to 50 μM may account for variability related to the
application of various concentrations of TAFIa (or CPB).
In vivo considerations
The normal plasma concentration of arginine of about 100 μM pro-
vides a baseline level of arginine, at which blood clots are formed
in vivo. However, in sepsis the systemic arginine concentration falls to
values below50 μM[45], whichmeans that locally, around inﬂammato-
ry cells expressing inducibleNO synthase, arginine could be severely de-
pleted. Furthermore, red blood cells contain high concentrations of
arginase I [46], which could deplete the arginine in erythrocyte-rich
thrombi. Thus, depending on the cell content of thrombi the arginine
concentrations can vary over a range capable of producing the effects
evaluated in the present study.
Our study demonstrates that carboxypeptidase-related modulation
of ﬁbrinolysis is more complex than generally believed. To date, down
regulation of ﬁbrinolysis in vivo has been ascribed to bypassing of the
positive feed-back loop in plasminogen activation or accelerated inacti-
vation of plasmin by α2-plasmin inhibitor in the lysing ﬁbrin. The
current study suggests inhibition of ﬁbrinolysis may be counteracted
to some degree by carboxypeptidases (TAFIa, CPN) effecting changes
in ﬁbrin ultrastructure to improve plasminogen activation rates and
by enhancing plasmin diffusion in ﬁbrin clots. Consideration of these
subtle effects and their balance appears essential in view of the recent
interest in TAFIa as a target of pharmacological agents for potential ad-
ministration as standalone or adjuvant thrombolytics (reviewed in
[47,48]) and the previously suggested regulatory role for the plasma
CPN under certain conditions [9,49].
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